TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07552077: A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

Sponsor: Palvella Therapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$896,400

Rescue Site Savings

+$597,600

Unlock Full NCT07552077 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07552077 Rescue Dossier →